Previous 10 | Next 10 |
2023-05-12 09:09:37 ET Protagonist Therapeutics ( NASDAQ: PTGX ) shared data from its partnership with Janssen Biotech, regarding the development of JNJ-2113. The pre-clinical data presented by Protagonist and Janssen Biotech on JNJ-2113 showed promising results in disease mod...
Protagonist Reports Positive Results from Phase 1 and Pre-clinical Studies of Oral Interleukin-23 Receptor Antagonist JNJ-2113 PR Newswire Data point to the potential of JNJ-2113 as a first-in-class drug candidate in multiple IL-23 driven-diseases NEWARK, Calif. ...
Protagonist Therapeutics to Participate in the JMP Securities Life Sciences Conference PR Newswire NEWARK, Calif. , May 11, 2023 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced that Dinesh V. Patel ...
Protagonist Therapeutics Announces Presentations at the 2023 Annual Congress of the European Hematology Association PR Newswire NEWARK, Calif. , May 11, 2023 /PRNewswire/ -- Protagonist Therapeutics (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced ...
2023-05-05 11:22:00 ET Protagonist press release ( NASDAQ: PTGX ): Q1 GAAP EPS of -$0.67 in-line. Cash, cash equivalents and marketable securities as of March 31, 2023 , were $230.8 million. Extended cash runway through end of 2025 with the completion ...
Protagonist Reports First Quarter 2023 Financial Results and Provides Corporate Update PR Newswire Announced positive topline results from the Phase 2b FRONTIER 1 study of JNJ-2113 (formerly PN-235), a first-in-class oral peptide for the treatment of moderate-to-severe pla...
2023-04-20 21:51:13 ET Shares of Protagonist Therapeutics (NASDAQ: PTGX) rose by 23.3% for the week, as of Thursday afternoon, according to data provided by S&P Global Market Intelligence . The clinical-stage biotech company's stock closed last week at $18.74 and rose to...
2023-04-05 10:07:20 ET Gainers: Liminal BioSciences ( LMNL ) +81% . InflaRx ( IFRX ) +51% . 180 Life Sciences ( ATNF ) +26% . YS Biopharma ( YS ) +22% . Immunic ( IMUX ) +21% . Losers: Bullfrog AI ( BFRG ) -15% ....
2023-04-05 03:14:12 ET Protagonist Therapeutics ( NASDAQ: PTGX ) prices its public offering of 5M shares at a public offering price of $20.00 per share. Gross proceeds are expected to be $100M. Underwriters a 30-day option to purchase up to 750K additional shares. ...
NEWARK, CA / ACCESSWIRE / April 4, 2023 / Protagonist Therapeutics (NASDAQ:PTGX) ("Protagonist" or the "Company") today announced the pricing of its previously announced underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $20.00 per share. Gross pro...
News, Short Squeeze, Breakout and More Instantly...
Protagonist Therapeutics Inc. Company Name:
PTGX Stock Symbol:
NASDAQ Market:
Protagonist Therapeutics Inc. Website:
NEWARK, CA / ACCESSWIRE / August 1, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced publication of preclinical and phase 1 clinical data on JNJ-2113 in the journal Scientific Reports , a Nature publication and the 5th most-cited journal in the world, acc...
Dr. Yeilding joins Protagonist from Janssen Pharmaceutical Companies of Johnson & Johnson, where he held leadership roles in the immunology therapeutic area, bringing extensive experience in R&D and commercialization of novel therapeutics in the I&I space NEWARK, CA / ACCESSWIRE /...
A look at the top 10 most actives in the United States Selina Hospitality PLC (SLNA) rose 75.8% to $0.0457 on volume of 1,196,767,473 shares NVIDIA Corporation (NVDA) fell 6.8% to $114.25 on volume of 316,196,296 shares Sangamo Therapeutics Inc. (SGMO) rose 39.5% to $0.56 on volume of 261...